vs
MESA LABORATORIES INC（MLAB）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
COMSCORE, INC.的季度营收约是MESA LABORATORIES INC的1.4倍（$93.5M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs 3.2%，领先2.3%），MESA LABORATORIES INC同比增速更快（3.6% vs -1.5%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $2.9M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 3.8%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
MLAB vs SCOR — 直观对比
营收规模更大
SCOR
是对方的1.4倍
$65.1M
营收增速更快
MLAB
高出5.2%
-1.5%
净利率更高
MLAB
高出2.3%
3.2%
自由现金流更多
MLAB
多$15.1M
$2.9M
两年增速更快
MLAB
近两年复合增速
3.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $93.5M |
| 净利润 | $3.6M | $3.0M |
| 毛利率 | 64.2% | 41.0% |
| 营业利润率 | 12.2% | 7.0% |
| 净利率 | 5.6% | 3.2% |
| 营收同比 | 3.6% | -1.5% |
| 净利润同比 | 316.6% | -3.7% |
| 每股收益（稀释后） | $0.65 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABSCOR
| Q4 25 | $65.1M | $93.5M | ||
| Q3 25 | $60.7M | $88.9M | ||
| Q2 25 | $59.5M | $89.4M | ||
| Q1 25 | $62.1M | $85.7M | ||
| Q4 24 | $62.8M | $94.9M | ||
| Q3 24 | $57.8M | $88.5M | ||
| Q2 24 | $58.2M | $85.8M | ||
| Q1 24 | $58.9M | $86.8M |
净利润MLABSCOR
| Q4 25 | $3.6M | $3.0M | ||
| Q3 25 | $2.5M | $453.0K | ||
| Q2 25 | $4.7M | $-9.5M | ||
| Q1 25 | $-7.1M | $-4.0M | ||
| Q4 24 | $-1.7M | $3.1M | ||
| Q3 24 | $3.4M | $-60.6M | ||
| Q2 24 | $3.4M | $-1.7M | ||
| Q1 24 | $-254.6M | $-1.1M |
毛利率MLABSCOR
| Q4 25 | 64.2% | 41.0% | ||
| Q3 25 | 61.5% | 40.6% | ||
| Q2 25 | 62.0% | 40.6% | ||
| Q1 25 | 61.8% | 39.6% | ||
| Q4 24 | 63.3% | 42.4% | ||
| Q3 24 | 61.3% | 41.2% | ||
| Q2 24 | 64.0% | 39.5% | ||
| Q1 24 | 62.1% | 42.3% |
营业利润率MLABSCOR
| Q4 25 | 12.2% | 7.0% | ||
| Q3 25 | 7.8% | 1.9% | ||
| Q2 25 | 5.1% | -1.9% | ||
| Q1 25 | 2.4% | -2.4% | ||
| Q4 24 | 9.2% | 4.1% | ||
| Q3 24 | 6.1% | -67.4% | ||
| Q2 24 | 9.6% | -2.2% | ||
| Q1 24 | -460.6% | -2.2% |
净利率MLABSCOR
| Q4 25 | 5.6% | 3.2% | ||
| Q3 25 | 4.1% | 0.5% | ||
| Q2 25 | 8.0% | -10.6% | ||
| Q1 25 | -11.4% | -4.7% | ||
| Q4 24 | -2.7% | 3.3% | ||
| Q3 24 | 5.9% | -68.5% | ||
| Q2 24 | 5.8% | -2.0% | ||
| Q1 24 | -432.2% | -1.2% |
每股收益（稀释后）MLABSCOR
| Q4 25 | $0.65 | $9.50 | ||
| Q3 25 | $0.45 | $-0.86 | ||
| Q2 25 | $0.85 | $-2.73 | ||
| Q1 25 | $-1.30 | $-1.66 | ||
| Q4 24 | $-0.31 | $-0.47 | ||
| Q3 24 | $0.63 | $-12.79 | ||
| Q2 24 | $0.62 | $-1.19 | ||
| Q1 24 | $-47.26 | $-1.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $23.6M |
| 总债务越低越好 | $68.4M | $41.5M |
| 股东权益账面价值 | $186.7M | $111.4M |
| 总资产 | $434.8M | $407.7M |
| 负债/权益比越低杠杆越低 | 0.37× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资MLABSCOR
| Q4 25 | $29.0M | $23.6M | ||
| Q3 25 | $20.4M | $26.7M | ||
| Q2 25 | $21.3M | $26.0M | ||
| Q1 25 | $27.3M | $31.0M | ||
| Q4 24 | $27.3M | $29.9M | ||
| Q3 24 | $24.3M | $20.0M | ||
| Q2 24 | $28.5M | $14.7M | ||
| Q1 24 | $28.2M | $18.7M |
总债务MLABSCOR
| Q4 25 | $68.4M | $41.5M | ||
| Q3 25 | $69.4M | $41.4M | ||
| Q2 25 | $70.3M | $41.3M | ||
| Q1 25 | $71.3M | $41.3M | ||
| Q4 24 | $72.2M | $41.2M | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABSCOR
| Q4 25 | $186.7M | $111.4M | ||
| Q3 25 | $178.5M | $-26.3M | ||
| Q2 25 | $172.5M | $-21.7M | ||
| Q1 25 | $159.8M | $-13.5M | ||
| Q4 24 | $155.2M | $-8.3M | ||
| Q3 24 | $161.5M | $-2.7M | ||
| Q2 24 | $150.7M | $45.8M | ||
| Q1 24 | $145.4M | $51.4M |
总资产MLABSCOR
| Q4 25 | $434.8M | $407.7M | ||
| Q3 25 | $430.4M | $406.9M | ||
| Q2 25 | $435.7M | $415.9M | ||
| Q1 25 | $433.3M | $421.5M | ||
| Q4 24 | $433.3M | $430.2M | ||
| Q3 24 | $454.1M | $412.5M | ||
| Q2 24 | $440.4M | $474.1M | ||
| Q1 24 | $446.8M | $477.7M |
负债/权益比MLABSCOR
| Q4 25 | 0.37× | 0.37× | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $2.9M |
| 自由现金流率自由现金流/营收 | 27.7% | 3.1% |
| 资本支出强度资本支出/营收 | 1.1% | 0.3% |
| 现金转化率经营现金流/净利润 | 5.17× | 1.07× |
| 过去12个月自由现金流最近4个季度 | $37.9M | $21.8M |
8季度趋势，按日历期对齐
经营现金流MLABSCOR
| Q4 25 | $18.8M | $3.2M | ||
| Q3 25 | $8.2M | $9.5M | ||
| Q2 25 | $1.9M | $932.0K | ||
| Q1 25 | $12.7M | $9.1M | ||
| Q4 24 | $18.1M | $-10.0M | ||
| Q3 24 | $5.3M | $12.5M | ||
| Q2 24 | $10.7M | $8.7M | ||
| Q1 24 | $12.9M | $6.9M |
自由现金流MLABSCOR
| Q4 25 | $18.0M | $2.9M | ||
| Q3 25 | $7.1M | $9.4M | ||
| Q2 25 | $884.0K | $787.0K | ||
| Q1 25 | $11.9M | $8.7M | ||
| Q4 24 | $17.3M | $-10.3M | ||
| Q3 24 | $3.5M | $12.4M | ||
| Q2 24 | $9.9M | $8.5M | ||
| Q1 24 | $12.3M | $6.6M |
自由现金流率MLABSCOR
| Q4 25 | 27.7% | 3.1% | ||
| Q3 25 | 11.7% | 10.5% | ||
| Q2 25 | 1.5% | 0.9% | ||
| Q1 25 | 19.2% | 10.1% | ||
| Q4 24 | 27.6% | -10.8% | ||
| Q3 24 | 6.0% | 14.0% | ||
| Q2 24 | 16.9% | 10.0% | ||
| Q1 24 | 21.0% | 7.6% |
资本支出强度MLABSCOR
| Q4 25 | 1.1% | 0.3% | ||
| Q3 25 | 1.8% | 0.1% | ||
| Q2 25 | 1.7% | 0.2% | ||
| Q1 25 | 1.2% | 0.4% | ||
| Q4 24 | 1.3% | 0.2% | ||
| Q3 24 | 3.1% | 0.1% | ||
| Q2 24 | 1.5% | 0.2% | ||
| Q1 24 | 0.9% | 0.3% |
现金转化率MLABSCOR
| Q4 25 | 5.17× | 1.07× | ||
| Q3 25 | 3.32× | 20.96× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
